1.Research progress in cancer genomics.
Chinese Journal of Oncology 2006;28(7):555-557
2.Peroxisome proliferator activated receptor gamma Pro12Ala: old topic of conversation and new question.
Acta Academiae Medicinae Sinicae 2011;33(6):591-592
Comments concerning Meta analysis for relationship between peroxisome proliferator activated receptor gamma Pro12Ala polymorphism and type 2 diabetes susceptibility in different cohorts in this mini review were given. The comments pointed out existent problems and presented suggestions for genetic analysis of diseases in Chinese populations.
Asian Continental Ancestry Group
;
genetics
;
Diabetes Mellitus, Type 2
;
genetics
;
Genetic Predisposition to Disease
;
Humans
;
PPAR gamma
;
genetics
;
Polymorphism, Genetic
4.Genetic analysis of complex diseases: status quo and prospects.
Acta Academiae Medicinae Sinicae 2009;31(6):661-663
This review comments the status quo, especially the major problems, of the genetic analysis of the complex diseases, provides some possible solutions, and explores the further development trends in this field.
Genetic Testing
;
Humans
5.The Economic Growth Effects of Health Investment and Regional Differences
Chinese Health Economics 2013;(9):30-32
Objective: To study the effect and contribution of health investment to economic growth as well as the regional differences among eastern, central and western China. Methods: Based on the provincial panel data from 1997 to 2010, fixed effects model was established to empirically analyze the relationship between health investment and economic growth. Results: Health Investment has significant in promoting economic growth, while significant regional differences still exist, showing the decreasing order of eastern、 central and western China. Conclusion:While strengthening the regional medical health level of investment, it is needed to give preferential policies to the backward central and western regions, so that the differences between regional economic growth and physical condition of residents can be reduced while realizing health investment stimulating economic growth.
6.New trends in research on cancer genomics.
Chinese Journal of Oncology 2007;29(7):544-544
DNA Methylation
;
DNA, Neoplasm
;
genetics
;
Genomics
;
trends
;
Human Genome Project
;
Humans
;
Neoplasms
;
genetics
;
Research
7.Research advances in sorafenib:a multiple targeted anti-tumor agent
Chinese Pharmacological Bulletin 2003;0(08):-
Sorafenib,a novel oral multikinase inhibitor,targts on serine/threonine kinase and tyrosine kinases receptor of the tumor cells and vasculature.So Sorafenib can inhibit the tumor cell proliferation and revascularization.400 mg sorafenib administered twice a day is chosen as the recommended dosage for several phase Ⅰ studies,and it shows broad-spectrum antitumor activity in renal cancer,hepatocellular carcinoma,melanoma and non-small-cell lung cancer(NSCLC)in phase Ⅱ and Ⅲ clinical trials.Now FDA has approved the usage of sorafenib in renal cancer therapy.
8.Prevention and management of hypertension in the patients with renal diseases
Chinese Journal of Practical Internal Medicine 2003;0(01):-
Effective management for hypertension in renal diseases should be carried out according to the principles of 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension.The important role of kidney in the classification of hypertension,the corresponding therapy,the set of the target blood pressure,the choice of antihypertensive agents and combination therapy should be focused.Comprehensive approaches should be used for the treatment of hypertension in renal diseases to protect the target organs(including the kidney).Appropriate prevention and management strategies for hypertension in renal diseases should be disseminated and optimized.
9.Topo II alpha in breast cancer: an update.
Jia WEI ; Fang-fang LIU ; Li FU
Chinese Journal of Pathology 2008;37(2):132-135
10.Effect of CXCL12 in tumor microenvironment.
Fang-Fang LIU ; Jia WEI ; Li FU
Chinese Journal of Pathology 2008;37(3):193-196